摘要
目的 探讨艾滋病患者的白念珠菌唑类耐药株中唑类抗真菌药物(氟康唑、伊曲康唑、伏立康唑)的作用靶位基因ERG 11基因突变与耐药的关系.方法 用PCR对临床分离的93株白念珠菌的Erg11基因进行扩增、测序,DNAman软件将测序结果与基因库中的X13296进行比对,将突变碱基翻译为氨基酸,确定是否发生错义突变.结果 共检出40个碱基突变位点,包括27个同义突变位点和13个错义突变位点.耐一种药物的突变菌株中每株菌只发生一处错义突变或无错义突变,而耐二种或三种药物的菌株中每株菌还可以同时出现两处或三处错义突变.结论 ERG 11基因错义突变与白念珠菌耐药有关.
Objective To investigate the relationship between the mutation of ERG11 gene,a target of azole antifungal drugs (fluconazole,itraconazole,voriconazole),and azole-resistance in Candida albicans isolates from patients with AIDS.Methods Ninety-three Candida albicans strains were isolated from patients with AIDS.DNA was extracted from these isolates,and ERG11 gene was amplified by PCR followed by bidirectional sequencing.DNAman software was used to compare the resultant sequence with the reference sequence of ERG11 gene (GenBank accession no.X13296).Then,different base sequences were translated into amino acid sequences to determine whether missense mutations occured.Results A total of 40 mutation sites were identified in these isolates,including 27 silent mutations and 13 missense mutations.One or no missense mutation was detected in Candida albicans strains resistant to 1 antifungal agent,while those resistant to 2 or 3 antifungal agents simultaneously harbored 2 or 3 missense mutations.Conclusion The missense mutations in ERG11 gene are probably connected with azole resistance in Candida albicans.
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2012年第1期32-34,共3页
Chinese Journal of Dermatology
基金
基金项目:卫生部艾滋病防治应用性研究项目(WA-2006-08):新疆医科大学研究生创新基金(MC2010-15)